Burden and clinical features of chronic obstructive pulmonary disease (COPD)

Lancet

Volumn 364, Issue 9434, 2004, Pages 613-620

  Pauwels, Prof Romain A ^a   Rabe, Klaus F ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN;

AGING; AIR POLLUTION; AIRFLOW; ALPHA 1 ANTITRYPSIN DEFICIENCY; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL FEATURE; CONFERENCE PAPER; COUGHING; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; ECONOMIC ASPECT; EXPOSURE; HEALTH CARE PERSONNEL; HEREDITY; HUMAN; INFLAMMATION; LUNG FUNCTION; MORBIDITY; MORTALITY; OCCUPATIONAL HEALTH; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION; SOCIAL CARE; SPIROMETRY; SPUTUM; STANDARDIZATION;

EID: 4143051640     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)16855-4     Document Type: Conference Paper

References (62)

1. WHO. World Health Report 2002.http://www.who.int/whr/2002
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 349:1997;1498-1504
3. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease.http://www.goldcopd.com (accessed July 27, 2004).
4. Vestbo J, Lange P. Can GOLD stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 166:2002;329-332
5. Vestbo J, Prescott E, Lange P, for the Copenhagen City Heart Study Group. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996; 153: 1530-1535.
6. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 167:2003;418-424
7. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med. 339:1998;1194-1200
8. Churg A, Brauer M, AvilaCasado MD, Fortoul TI, Wright JL. Chronic exposure to high levels of particulate air pollution and small airway remodeling. Environ Health Perspect. 111:2003;714-718
9. Pena VS, Miravitlles M, Gabriel R, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. Chest. 118:2000;981-989
10. Mannino DM, Homa DM, Akimbani LJ, Ford ES, Redd SC. Chronic Obstructive Pulmonary Disease Surveillance-United States, 1971-2000. MMWR. 51:2002;1-16
11. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Resp Med. 97:2003;115-122
12. de Marco R, Accordini S, Cerveri I, et al, for the European Community Health Survey Study Group. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Thorax 2004; 59: 120-125
13. Rennard S, Decramer M, Calverley PM, et al. Impact of COPD in North America and Europe in: subjects' perspective of Confronting COPD International Survey. Eur Respir J. 20:2002;799-805
14. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 56:2001;880-887
15. Peruzza S, Sergi G, Vianello A, et al. Chronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status and quality of life. Resp Med. 97:2003;612-617
16. Calverley PMA. Chronic Obstructive Pulmonary Disease: the key facts. 1998;British Lung Foundation, London
17. National Heart, Lung and Blood Institute. Morbidity and mortality: chartbook on cardiovascular, lung and blood diseases. Bethesda: US Department of Health and Human Services, Public Health Service, National Institutes of Health, 1998. http://www.nhlbi.nih.gov/nhlbi/seiin/other/cht-book/htm.
18. Jacobson L, Hertzman P, Lofdahl C-G, Skoogh B-E, Lindgren B. The economic impact of asthma and COPD in Sweden 1980 and 1991. Respir Med. 94:2000;247-255
19. National Health Service Executive. Burdens of disease: a discussion document. 1996;Department of Health, London
20. Chen JC, Mannino MD. Worldwide epidemiology of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 5:1999;93-99
21. Singh GK, Matthews TJ, Clarke SC. Annual summary of births, marriages, divorces, and deaths: United States,1994. Monthly Vital Statistics Report. 14:1994;14
22. Strassels SA, Smith DH, Sullivan SD, Mahajan PS. The costs of treating COPD in the United States. Chest. 119:2001;344-352
23. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med. 166:2002;675-679
24. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. Requirement for macrophage elastase for cigarette smoke-i nduced emphysema in mice. Science. 277:1997;2002-2004
25. Coultas DB. Health effects of passive smoking. 8. Passive smoking and risk of adult asthma and COPD: an update. Thorax. 53:1998;381-387
26. Amoli K. Bronchopulmonary disease in Iranian housewives chronically exposed to indoor smoke. Eur Respir J. 11:1998;659-663
27. Pandey MR. Domestic smoke pollution and chronic bronchitis in a rural community of the Hill Region of Nepal. Thorax. 39:1984;337-339
28. Perez-Padilla R, Regalado J, Vedal S, et al. Exposure to biomass smoke and chronic airway disease in Mexican women: a case-control study. Am J Respir Crit Care Med. 154:1996;701-706
29. Smith KR. Inaugural article: national burden of disease in India from indoor air pollution. Proc Natl Acad Sci USA. 97:2000;13286-13293
30. Murray CJ, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet. 349:1997;1436-1442
31. Kauffmann F, Drouet D, Lellouch J, Brille D. Occupational exposure and 12-year spirometric changes among Paris area workers. Br J Ind Med. 39:1982;221-232
32. Vogelzang PF, van der Gulden JW, Folgering H, et al. Endotoxin exposure as a major determinant of lung function decline in pig farmers. Am J Respir Crit Care Med. 157:1998;15-88
33. Eriksson S. Studies in alpha 1-antitrypsin deficiency. Acta Med Scand Suppl. 432:1965;1-85
34. Stoller JK. Clinical features and natural history of severe alpha 1-antitrypsin deficiency. Roger S. Mitchell Lecture. Chest. 111:1997;123-128S
35. Sandford AJ, Silverman EK. Chronic obstructive pulmonary disease. Susceptibility factors for COPD the genotype-environment interaction. Thorax. 57:2002;736-741
36. Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease-Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med. 157:1998;1770-1778
37. Georgopoulos D, Anthonisen NR. Symptoms and signs of COPD. Cherniack NS. Chronic obstructive pulmonary disease. 1991;357-363 WB Saunders, Toronto
38. Burrows B, Niden AH, Barclay WR, Kasik JE. Chronic obstructive lung disease II. Relationships of clinical and physiological findings to the severity of airways obstruction. Am Rev Respir Dis. 91:1965;665-678
39. Medical Research Council. Definition and classification of chronic bronchitis for clinical and epidemiological purposes: a report to the Medical Research Council by their Committee on the Aetiology of Chronic Bronchitis. Lancet. 1:1965;775-780
40. Simon PM, Schwartstein RM, Weiss JW, Fencl V, Teghtsoonian M, Weinberger SE. Distinguishable types of dyspnea in patients with shortness of breath. Am Rev Respir Dis. 142:1990;1009-1014
41. Elliott MW, Adams L, Cockcroft A, MacRae KD, Murphy K, Guz A. The language of breathlessness: use of verbal descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis. 144:1991;826-832
42. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 54:1999;581-586
43. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 147:1993;1151-1156
44. Johnston RN, Lockhart W, Ritchie RT, Smith DH. Haemoptysis. BMJ. 1:1960;592-595
45. Calverley PM. Neuropsychological deficits in chronic obstructive pulmonary disease. Monaldi Archives for Chest Disease. 51:1996;5-6
46. Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest. 104:1993;254-258
47. Loveridge B, West P, Kryger MH, Anthonisen NR. Alteration of breathing pattern with progression of chronic obstructive pulmonary disease. Am Rev Respir Dis. 134:1986;930-934
48. Badgett RC, Tanaka DV, Hunt DK, et al. Can moderate chronic obstructive pulmonary disease be diagnosed by history and physical findings alone? Am J Med. 94:1993;188-196
49. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 164:2001;770-777
50. Marin JM, Carrizo SJ, Gascon M, Sanchez A, Gallego B, Celli BR. Inspiratory capacity, dynamic hyperinflation, breathlessness, and exercise performance during the 6-minute-walk test in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 163:2001;1395-1399
51. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136.
52. Kelly CA, Gibson GJ. Relation between FEV 1 and peak expiratory flow in patients with chronic obstructive pulmonary disease. Thorax. 43:1988;335-336
53. Lal S, Ferguson AD, Campbell EJM. Forced expiratory time; a simple test for airways obstruction. BMJ. 1:1964;814-817
54. Swanney MP, Jensen RL, Crichton DA, Beckert LE, Cardno LA, Crapo RO. FEV(6) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med. 162:2000;917-919
55. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: a consensus statement from the national lung health education program. Chest. 117:2000;1146-1161
56. Russi EW, Weder W. News on lung volume reduction surgery. Swiss Med Wkly. 132:2002;557-561
57. Calverley PM, Leggett RJ, McElderry L, Flenley DC. Cigarette smoking and secondary polycythemia in hypoxic cor pulmonale. Am Rev Respir Med. 125:1982;507-510
58. Rutgers SR, Postma DS, ten Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax. 55:2000;12-18
59. Antonelli-Incalzi R, Imperiale C, Bellia V, et al. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J. 22:2003;444-449
60. Celli BR, Cot CJ, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. New Engl J Med. 350:2004;1005-1012
61. Fletcher C, Peto R. The natural history of chronic airflow obstruction. BMJ. 1:1997;1645-1648
62. Celli BR, MacNee W, and committee members. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper, Eur Respir J 2004; 23: 932-46.